Results 231 to 240 of about 166,355 (310)

Fat Mass and Obesity‐Associated Protein Contributes to Tumorigenesis and Drug Resistance of Diffuse Large B‐Cell Lymphoma by Suppressing N6‐Methyladenosine Methylation of Myc

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Ibrutinib resistance remains a major obstacle in the treatment of diffuse large B‐cell lymphoma (DLBCL). Fat mass and obesity‐associated protein (FTO) has been implicated in drug resistance through its regulation of N6‐methyladenosine (m6A) modifications; however, whether FTO mediates ibrutinib resistance in DLBCL remains unclear.
Ting‐Ting Lu, Jin‐Hao Chen, Yan‐Fang Wang, Xiao Wu, Hui‐Yun Ni, Qiu‐Rong Zhang   +5 more
wiley   +1 more source

Oncogenic KRAS Rewires Stress Granule Dynamics: Mechanisms and Therapeutic Opportunities

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Stress granules (SGs) are dynamic, membrane‐less structures that form in response to various cellular stresses, including metabolic, oxidative, and therapeutic challenges. They function as adaptive hubs and reorganize protein synthesis and signaling networks to help cells survive under stress. In cancer, these condensates are often hijacked to
Msimisi Ndzinisa, Birhanetensay Masresha Altaye, Yuh‐Pyng Sher   +2 more
wiley   +1 more source

Prognostic Value of Impaired Vocal Cord Mobility in T2N0 Glottic Cancer Treated With IMRT

The Laryngoscope, EarlyView.
T2N0M0 glottic cancers with impaired vocal cord mobility (VCM) have worse outcomes than T2N0M0 tumors with normal VCM, but still fare better than T3N0M0 disease. These findings support subdivision of T2 glottic cancer into T2a (normal VCM) and T2b (impaired VCM) in future TNM revisions.
Alexander Rühle, Ranjan Subramani, Jie Su, Brian O'Sullivan, John N. Waldron, Andrew Hope, Andrew Bayley, Andrew McPartlin, Nauman Malik, Scott V. Bratman, Ali Hosni, John Kim, Ian Witterick, John R. de Almeida, Christopher Yao, Anna Spreafico, C. Jillian Tsai, Li Tong, Wei Xu, Shao Hui Huang, Ezra Hahn   +20 more
wiley   +1 more source

Cisplatin resistance

, 1995
openaire   +1 more source

RETRACTION: UBE2C Induces Cisplatin Resistance via ZEB1/2-Dependent Upregulation of ABCG2 and ERCC1 in NSCLC Cells. [PDF]

J Oncol
Oncology JO.
europepmc   +1 more source

Machine Learning‐Driven Predictive Modeling and Multi‐Objective Exploration of Oxaliplatin‐Loaded Nanocarriers for Enhanced Loading and Encapsulation Efficiency

Materials Genome Engineering Advances, EarlyView.
Integrating ML and multi‐objective optimization enabled efficient, accurate design of nanocarriers with optimized loading and encapsulation efficiencies. ABSTRACT Oxaliplatin (OXA), a critical third‐generation platinum chemotherapeutic, is significantly limited by suboptimal loading capacity and encapsulation efficiency in nanoparticle‐based delivery ...
Abbas Rahdar, Maryam Shirzad, Sonia Fathi‐Karkan, M. Ali Aboudzadeh   +3 more
wiley   +1 more source

A stress granule-associated RNA-binding protein FAM120A drives cisplatin resistance in non-small cell lung cancer. [PDF]

J Biochem
Hayai S, Suzuki MM, Iijima K, Shinjo K, Murofushi Y, Xie J, Nishimura T, Ishii M, Kondo Y.   +8 more
europepmc   +1 more source

Harnessing Phytochemicals for Brain Cancer Therapy: Insights Into Medulloblastoma and Glioblastoma Treatment

Phytochemical Analysis, EarlyView.
ABSTRACT Primary brain tumors are life‐threatening diseases. Glioblastoma is the most aggressive type with a poor prognosis. Medulloblastoma is the most common pediatric brain tumor. While surgical treatments often result in recurrences owing to the complex nature of the tumor microenvironment, conventional treatments lower the quality of life of ...
Ilkay Irem Ozbek, Mesra Aktas, Hale Saybasili, Kutlu O. Ulgen   +3 more
wiley   +1 more source

ULK2 suppresses glycolysis to attenuate cisplatin resistance in ovarian cancer organoid via c-Jun phosphorylation. [PDF]

Sci Prog
Chen W, Chen X, Wang L, Qu Y, Zhao J, Sun H.   +5 more
europepmc   +1 more source

Traditional Chinese Medicine for lung cancer: Mechanisms, clinical evidence, and future perspectives

Precision Medical Sciences, EarlyView.
Graphical abstract represents the risk factors for lung cancer, TCM efficacy and clinical outcomes to future challenges. Abstract Lung cancer remains a leading cause of global cancer mortality. Despite advances in conventional treatments such as surgery, chemotherapy, targeted therapy, and immunotherapy, challenges including drug resistance, toxicity ...
Zhangdeng Chen, Liujun Bao
wiley   +1 more source